iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares Purchased by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC boosted its stake in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) by 4,094.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 18,412 shares of the company’s stock after buying an additional 17,973 shares during the quarter. Allspring Global Investments Holdings LLC owned 0.05% of iTeos Therapeutics worth $202,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in the stock. PNC Financial Services Group Inc. boosted its stake in shares of iTeos Therapeutics by 131.5% during the 3rd quarter. PNC Financial Services Group Inc. now owns 2,287 shares of the company’s stock worth $25,000 after acquiring an additional 1,299 shares in the last quarter. Amalgamated Bank boosted its position in iTeos Therapeutics by 14.7% during the third quarter. Amalgamated Bank now owns 10,574 shares of the company’s stock worth $116,000 after purchasing an additional 1,357 shares in the last quarter. Exchange Traded Concepts LLC grew its holdings in iTeos Therapeutics by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 11,379 shares of the company’s stock valued at $125,000 after purchasing an additional 2,885 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of iTeos Therapeutics by 348.1% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 4,140 shares of the company’s stock valued at $45,000 after buying an additional 3,216 shares in the last quarter. Finally, Trexquant Investment LP raised its stake in shares of iTeos Therapeutics by 10.8% during the 3rd quarter. Trexquant Investment LP now owns 33,549 shares of the company’s stock worth $367,000 after buying an additional 3,268 shares during the last quarter. 97.16% of the stock is owned by hedge funds and other institutional investors.

iTeos Therapeutics Price Performance

NASDAQ ITOS opened at $10.80 on Friday. The company has a market cap of $387.07 million, a P/E ratio of -3.43 and a beta of 1.19. iTeos Therapeutics, Inc. has a 12 month low of $8.20 and a 12 month high of $18.24. The company has a 50-day moving average of $11.45 and a 200-day moving average of $10.61.

iTeos Therapeutics (NASDAQ:ITOS) last issued its earnings results on Wednesday, March 6th. The company reported ($0.85) earnings per share for the quarter, topping the consensus estimate of ($1.03) by $0.18. As a group, equities research analysts anticipate that iTeos Therapeutics, Inc. will post -4.76 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently commented on ITOS. HC Wainwright reissued a “buy” rating and issued a $44.00 price objective on shares of iTeos Therapeutics in a research note on Thursday, March 7th. Wedbush reiterated an “outperform” rating and issued a $18.00 price target (down from $25.00) on shares of iTeos Therapeutics in a research report on Wednesday, March 6th.

About iTeos Therapeutics

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.